Overview of U.S. National Cancer Institute (USNCI) chemoprevention research.
The National Cancer Institute's (NCI) chemoprevention plan employs a strategy of basic and epidemiologic studies, followed by a structured preclinical process to bring chemopreventive agents into clinical testing. The field of chemoprevention is progressing rapidly and has reached the point where a coordinated international approach for large-scale trials would be useful. At present, NCI is sponsoring nine large trials (over $1 million per year per trial); in addition, nine agents are in phase I or II clinical testing. A number of these agents should be ready soon for phase III testing. Resources required for large-scale trials compel greater attention to efficient trial design, concept development and review, priority setting, management, budgeting, and collaboration.
Johnson
K A
KA
Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, Maryland 29892.
Ford
L G
LG
Kramer
B
B
Greenwald
P
P
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000517:prevention & control*; D012106:Research; D014481:United States
D000970:Antineoplastic Agents